Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical Trials NEW YORK, NY--(Marketwired - Mar 3, 2014) - Nuvilex (OTCQB: NVLX) investors who have patiently waited for the R&D biotech to reach a point where late-phase clinical trials were a reality, are...

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly NEW YORK, NY--(Marketwired - Feb 24, 2014) - Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be...

Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials NEW YORK, NY--(Marketwired - Feb 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the...

Nuvilex, Inc.'s COO, Dr. Gerald Crabtree, Interviews With Stock Market Media Group NEW YORK, NY--(Marketwired - Oct 17, 2013) - Nuvilex Inc.'s, (OTCQB: NVLX) Chief Operating Officer, Dr. Gerald Crabtree sat down for an interview with Stock Market Media Group, a research and...